uniQure N.V.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Accelerated filer
Country Netherlands
Business Address PAASHEUVELWEG 25A, AMSTERDAM, , 1105 BP
Mailing Address PAASHEUVELWEG 25A, AMSTERDAM, , 1105 BP
Phone 1-339-970-7000
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2024
$-4.92
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 13, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 9, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 29, 2026 | View on SEC |
| 4 Insider stock transaction report | January 14, 2026 | View on SEC |
| 8-K Current report of material events | January 13, 2026 | View on SEC |
| 4 Insider stock transaction report | January 12, 2026 | View on SEC |
| 8-K Current report of material events | January 9, 2026 | View on SEC |
| 8-K Current report of material events | December 4, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
Insider Trading
STRONG SELL 2 insiders
4 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.